Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Pasquale Striano MD, PhD

Pasquale Striano MD, PhD

Professor of Pediatrics, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy; IRCCS Istituto Giannina Gaslini, Genoa, Italy

Professor Striano, a board-certified neurologist and pediatric neurologist, is Full Professor of Paediatrics at the University of Genoa, IRCCS Istituto Giannina Gaslini. He has conducted translational studies on different forms of genetic epilepsies and participated to clinical trials of antiepileptic drugs in patients affected by seizure disorders. He is member of the Board of Italian League Against Epilepsy (LICE), a scientific association that is focused on promoting knowledge of the Epilepsy among people and among physicians to improve the care of patients.

Prof. Striano is associate partner of the EUROEPINOMICS consortium for study of genetic epilepsies through Next Generation (NGS) sequencing techniques and has awarded by the ILAE the Young Investigator Award at the European Congress of Epileptology, London, November 2012. From 2013 he is Member of the Pediatric Committee of Italian Medicines Agency (AIFA).

Disclosures

Professor Striano has served on a scientific advisory board for the Italian Agency of the Drug (AIFA); has received honoraria from Jazz Pharmaceuticals, Kolfarma s.r.l., Proveca Pharma Ltd, UCB Pharma, and Eisai Inc.; and has received research support from the Italian Ministry of Health and Fondazione San Paolo.